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Cigarette smoking causes inflammatory responses in the airways. However, not all smokers
exhibit the development of airflow limitation. This study was designed to determine the impli-
cations of small airways inflammation in the development of airflow limitation in smokers by
our newly explored method. Twenty-eight smokers (15 smokers without airflow limitation
and 13 with airflow limitation) were included in this study. Levels of interleukin-8 (IL-8) and
8-isoprostane were measured in epithelial lining fluid (ELF) from central and peripheral
airways separately collected using a bronchoscopic microsampling technique. 8-isoprostane
levels in ELF from central or peripheral airways did not significantly differ between the two
groups. However, these levels were markedly higher in peripheral than in central airways.
Similarly, IL-8 levels in ELF from central airways did not significantly differ between the two
groups. In smokers without airflow limitation, IL-8 levels were not higher in peripheral than
in central airways. In contrast, in smokers with airflow limitation, IL-8 levels were significantly
higher in peripheral airways. Moreover, in smokers with airflow limitation, 8-isoprostane levels
in central or peripheral airways were not significantly correlated with FEV1. However, IL-8
levels in peripheral airways were inversely correlated with FEV1, though those levels in central
airways were not. Thus our technique provides a novel method for ELF sampling from central or
peripheral airways separately, and the preliminary evidence that support differences in oxida-
tive stress and neutrophil chemotactic stimulus in these two locations.
ª 2008 Elsevier Ltd. All rights reserved.6645 3801; fax: þ81 6 6645
saka-cu.ac.jp (H. Kanazawa).
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Chronic obstructive pulmonary disease (COPD) is a major
worldwide health problem that has an increasing preva-
lence and mortality.1 The prevalence, morbidity, and
mortality of COPD vary appreciably across countries, but in.
Table 1 Clinical characteristics of study subjects
Current smokers
Without airflow
limitation
With airflow
limitation
Subject no. (male/female) 15 (12/3) 13 (12/1)
Age (yr) 69 (9) 64 (14)
Smoking index (pack-yr) 48 (25) 49 (43)
FEV1 (% predicted) 126 (21) 67 (18)
a
Dlco (%) 93 (22) 85 (25)a
All values are presented as mean (SD).
Definition of abbreviations: FEV1Z forced expiratory volume in
1 s, DlcoZ diffusing capacity of carbon monoxide.
a p< 0.01 Compared with smokers without airflow limitation.
36 T. Kodama et al.general are directly related to the prevalence of cigarette
smoking. COPD is a disease state characterized by airflow
limitation that is not fully reversible, usually progressive,
and associated with an abnormal inflammatory response of
the lungs. Indeed, one important pathological feature of
COPD is chronic airway inflammation characterized by an
influx of inflammatory cells e predominantly neutrophils,
macrophages and CD8þ T lymphocytes e in the lumen and
wall of the bronchial and bronchiolar airways and paren-
chyma.2 One prevalent theory concerning the pathogenesis
of COPD is of an abnormal balance between proteases and
anti-proteases in the lung.3 This theory proposes that
increased numbers of neutrophils, activated by cigarette
smoke, produce large amounts of proteases and oxidants
responsible for lung destruction. Thus, increased oxidative
stress, which can be defined as an increased exposure to
oxidants and decreased antioxidant capacities, is widely
recognized as a central feature of COPD.4 Since increased
oxidative stress leads to extensive cellular injury and
damage, oxidants produced by pulmonary inflammatory
cells play an important role in the pathophysiology of
COPD. However, the initial inflammatory properties of this
disease have not yet been fully elucidated.
Cigarette smoking causes inflammatory responses in the
airways.5 These changes include infiltration of inflamma-
tory cells such as neutrophils and macrophages, and
thickening of the airway walls with increased collagen
deposition.6 Such inflammatory and remodeling processes
are believed to be related to the resultant obstructive
changes in the airways. These smoking-related changes in
the airways impose a major risk for the development of
COPD. Stefano and coworkers have already demonstrated
that airflow limitation is associated with severity of airway
inflammation in smokers.7 Moreover, it has been shown that
smoking can progress airflow limitation, as evidenced by an
increase in the rate of decline in forced expiratory volume
in 1 s (FEV1).8 In particular, it is well known that smoking-
induced structural changes mainly originate in the peripheral
airways.9 However, not all smokers exhibit the develop-
ment of airflow limitation, which suggest that various
factors in each individual susceptible to cigarette smoking
may modify lung function abnormalities.10 On the basis of
these findings, we hypothesized that differences in
inflammatory properties of small airways may exist in
smokers with and without airflow limitation. To test our
hypothesis, a sensitive method to investigate characteris-
tics of small airways will be required. In this study, to
evaluate the properties of small airways inflammation in
the development of airflow limitation, levels of interleukin-
8 (IL-8) and 8-isoprostane were measured in epithelial
lining fluid (ELF) from central and peripheral airways
separately collected from smokers with and without airflow
limitation using a bronchoscopic microsampling technique.
Methods
Subjects
This study prospectively enrolled 28 current smokers from
the outpatient clinic of our institution, who underwent
bronchoscopy to identify the cause of persistent cough orsmall peripheral nodules. All smoking subjects who agreed
to address ELF samplings were randomly selected. Chest
computed tomographic scans showed no abnormal diffuse
interstitial infiltrates, and results of arterial blood gas
analyses were normal. We divided these subjects into two
groups based on a pulmonary functional viewpoint (15
smokers without airflow limitation (FEV1/FVC> 70%) and 13
smokers with airflow limitation (FEV1/FVC< 70%)). All
subjects gave their written informed consent for partici-
pation in the study, which was approved by the Ethics
Committee of Osaka City University.
Bronchoscopic microsampling technique
The interval time from the last cigarette smoking in each
subject was at least more than 24 h. ELF was obtained using
a previously described bronchoscopic microsampling tech-
nique.11,12 In brief, after premedication of the subject with
atropine and pentazocine, and administering local anes-
thesia with aerosolized lidocaine hydrochloride, a flexible
fiberoptic bronchoscope (BF-240, Olympus, Tokyo, Japan)
was inserted in the trachea and, after flushing with air to
minimize contamination of the samples, advanced into the
target bronchus. Subsequently, the microsampling probe
(BC-402C, Olympus, Tokyo, Japan) was then inserted
through the channel of the bronchoscope. The probe
consists of a 2.5-mm outer diameter polyethylene sheath
and a 1.9-mm inner polyester fiber rod probe attached to
a stainless steel guide wire. Bronchial microsampling
techniques were performed in all subjects from the right
bronchus intermedius (central airways). Next, a thin flex-
ible fiberoptic bronchoscope (BF-P260F, Olympus, Tokyo,
Japan) was inserted into the lung, and the microsampling
probe (BC-401C, Olympus, Tokyo, Japan) was then inserted
through the channel of the bronchoscope. This probe
consists of a 1.8-mm outer diameter polyethylene sheath
and a 1.1-mm inner polyester fiber rod. We obtained ELF
from seventh or eighth lower lobe bronchioles under direct
vision using this thin bronchofiber scope in the same
subjects (peripheral airways). ELF was collected in each
subject from the contralateral lung field of small peripheral
nodules. The inner probe was advanced into the bronchial
lumen slowly for 15 s to avoid injuring the bronchial wall.
The inner probe was then withdrawn into the outer tube,
and both were withdrawn together to avoid contamination.
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Figure 1 Correlations between smoking index and IL-8 levels in ELF from central or peripheral airways for all study subjects.
ELF in peripheral airways of smokers 37Thus, the same procedure was repeated three times. And
then the inner probe was cut at 3 cm distal from its tip, and
the wet probe was frozen at a 80 C freezer until use. The
diluted solution for measurements of biochemical constit-
uents was prepared by adding 1 ml of saline to the tube
containing the frozen probe and vortexed for 1 min. The
probe was dried and weighed to measure the ELF volume
recovered, and the dilution factor was calculated.
Measurement of biochemical constituents in ELF
Using the ELF sample processed as above mentioned, the
concentration of 8-iso-prostaglandin F2a (8-isoprostane),13
one of the major biomarkers of oxidative stress, was detec-
ted by enzyme-linked immunosorbent assay (ELISA) (Cayman
Chemical, Ann Arbor, MI). The assay for 8-isoprostane has
4 pg/mL detection limit, using antiserum that has 100%
reactivity with 8-isoprostane. The concentrations of IL-8
were also measured using commercial ELISA kits (BioSource,
Belgium). The detection limit for IL-8 was 8 pg/mL.
Statistical analysis
All values are presented as mean (SD) or median [range]
depending on whether they were normally distributed. The
unpaired t-test was used for comparisons of parametric
data. When multiple comparisons of nonparametric data
were made between groups, significant intergroup0
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Figure 2 Comparisons of 8-isoprostane levels in ELF from centr
limitation.variability was first established by using the KruskaleWallis
test. The ManneWhitney U-test was then used for inter-
group comparisons. The Wilcoxon signed-rank test was also
used for comparisons of variables between central and
peripheral airways. The significance of correlations was
evaluated by determining Spearman’s rank correlation
coefficients. A p-value of less than 0.05 was considered
significant.
Results
The clinical characteristics of 15 smokers without airflow
limitation (FEV1/FVC> 70%) and 13 smokers with airflow
limitation (FEV1/FVC< 70%) are shown in Table 1. The two
groups were well matched for age and smoking index,
though FEV1 and Dlco were significantly lower in smokers
with airflow limitation. We could safely accomplish bron-
choscopic microsampling techniques in all study subjects.
For all study subjects, smoking index was significantly
correlated with IL-8 levels in ELF from central airways
(rZ 0.41, pZ 0.03), but not with those levels from
peripheral airways (Fig. 1).
8-isoprostane levels in ELF from central or peripheral
airways did not significantly differ between the two groups
(without airflow limitation: central 0.75 [0e4.4] ng/ml,
peripheral 6.6 [0e19.6] ng/ml; with airflow limitation:
central 0.43 [0e5.7] ng/ml, peripheral 3.7 [0e18.4] ng/ml)
(Fig. 2). However, these levels were markedly higher incentral peripheral
Smokers with airflow limitation
p = 0.02
al and peripheral airways in smokers with or without airflow
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Figure 3 Comparisons of IL-8 levels in ELF from central and peripheral airways in smokers with or without airflow limitation.
38 T. Kodama et al.peripheral than in central airways (without airflow limita-
tion: pZ 0.02; with airflow limitation: pZ 0.02). Similarly,
IL-8 levels in ELF from central airways did not significantly
differ between the two groups (without airflow limitation:
22.3 [2.5e58.5] ng/ml; with airflow limitation: 11.2 [2.3e
80.5] ng/ml) (Fig. 3). These levels in smokers without
airflow limitation were not significantly higher in peripheral
than in central airways. In contrast, these levels in smokers
with airflow limitation were significantly higher in periph-
eral than in central airways (pZ 0.046).
In smokers with airflow limitation, we evaluated the
correlations between degree of airflow limitation and levels
of IL-8 or oxidative stress. 8-isoprostane levels in central or
peripheral airways were not significantly correlated with
FEV1 (Fig. 4). Similarly, IL-8 levels in central airways were
not also correlated with FEV1 (Fig. 5). However, these levels
in peripheral airways were inversely correlated with FEV1
(rZ0.64, pZ 0.026).
Discussion
The bronchoscopic microsampling techniques have meth-
odological advantages compared with sputum or bron-
choalveolar lavage fluid sampling techniques by enabling
quantitative analysis. These advantages encouraged us to
utilize this technique to obtain ELF samples in human
subjects and to assess the inflammatory markers30
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Figure 4 Correlations between 8-isoprostane levels in ELF from
limitation.quantitatively. Moreover, a recent clinical interest has been
devoted to a sensitive method explored for early detection
of small airways inflammation in smokers. From these
viewpoints, we developed a new method to obtain ELF
samples separately from central and peripheral airways
using a thin fiberoptic bronchoscope. Using this method, we
found that 8-isoprostane levels in ELF from central or
peripheral airways did not significantly differ between
smokers with and without airflow limitation, but that these
levels were markedly higher in peripheral than in central
airways in the two groups. 8-isoprostane is considered to be
a reliable index of in vivo oxidative stress because they are
structurally stable and are produced in vivo.14 Many
previous studies have demonstrated that increased
concentrations of 8-isoprostane are a common feature of
chronic inflammatory diseases.15 In fact, elevated 8-iso-
prostane concentrations in induced sputum and exhaled
breath condensate have been reported in patients with
asthma, COPD, and interstitial lung disease.16 These
reports highlight the involvement of oxidative stress in
various inflammatory lung diseases. However, in this study
we found that elevated levels of oxidative stress may not
be the sole mechanism responsible for the manifestation of
airflow limitation in smokers.
The second novel aspect of this investigation is the
finding that (i) IL-8 levels in ELF from central airways did
not significantly differ between smokers with and without30
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Figure 5 Correlations between IL-8 levels in ELF from central or peripheral airways and FEV1 in smokers with airflow limitation.
ELF in peripheral airways of smokers 39airflow limitation, (ii) IL-8 levels in ELF from peripheral
airways in smokers with airflow limitation, but not in
smokers without airflow limitation, were significantly
higher than those from central airways, and (iii) in smokers
with airflow limitation, IL-8 levels in ELF from peripheral
airways were associated with severity of airflow limitation.
IL-8 is a cytokine synthesized by a variety of inflammatory
cells in the lung, and a potent activator of neutrophils.17 IL-8
induces superoxide anion release from neutrophils in vitro,
and intravenous administration of IL-8 in vivo has been
reported to induce accumulation of neutrophils in the lung.
Therefore, expression of IL-8 may be critically important in
the pathogenesis of smoking-induced lung diseases. In this
study, we found a significant correlation between smoking
index and IL-8 levels in ELF from central airways. However,
we could not observe a significant correlation between
smoking index and those levels from peripheral airways.
These findings suggest that total amounts of cigarette
smoking are associated with magnitude of neutrophilic
inflammation in central airways, and that not all smokers
demonstrated neutrophil chemotaxis into peripheral
airways. Thus, neutrophil chemotaxis into peripheral
airways may be, at least in part, responsible for the
manifestation of airflow limitation in smokers. In the
present study, we found that concentration of IL-8 in
peripheral airways of smokers with airflow limitation was
higher than those in central airways, and that peripheral IL-8
levels were associated with airflow limitation in these
patients. Local migration of neutrophils might be induced
by the direct effect of tobacco contents,18 and, however,
additional findings suggested that cigarette smoke stimu-
lated airway epithelial cells to release chemotactic factors
for neutrophils such as IL-8.19 In fact, the mRNA levels of IL-8
were increased in small airway epithelial cells from
smokers as compared with nonsmokers.20 Moreover, since
IL-8 is also one of proangiogenic factors,21 higher levels of
IL-8 in small airways may be important in the development
of small airways remodeling.
Based on the results of this study, we hypothesized that
neutrophilic inflammation in the peripheral airways appears
to play an important role in the pathogenesis of smoking-
induced airway dysfunction. Future studies of the patho-
genesis of smoking-induced airway dysfunction would focus
on theaccumulation andactivation of neutrophils stimulated
by IL-8 in the peripheral airways. However, there are several
limitations in this study to reinforce our results. First, this
preliminary study had a limited sample size. Second, a group
of healthy nonsmoking subjects to clarify the direct effectsof smokingwere not included for an ethical reason. However,
our new method in ELF sampling technique seems to avoid
the difficulties in ELFmeasurement inherent in estimation of
ELF from BAL fluid sampling or induced sputum. An accurate
ELF measurement in the lungs will be potentially important
area for a number of reasons including pathophysiological
studies of various pulmonary diseases and assessment of
pharmacological treatments. In summary, a less invasive and
quantitative bronchoscopic microsampling technique was
newly explored to measure biochemical constituents in ELF
separately from central or peripheral airways. Using this new
method, we for the first time showed increased levels of IL-8
in ELF from peripheral airways of smokers with airflow limi-
tation comparedwith thosewithout airflow limitation. These
findings may shed new light on the pathogenesis of smoking-
induced airway dysfunction. It is also clear that IL-8 in
peripheral airways could be an interesting target for new
pharmacological treatments in smokers with airflow
limitation.
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